More often than not, the most vulnerable countries are usually forgotten when it comes to the distribution of new treatments. This should not be the case for COVID-19 vaccines since the pandemic has affected both wealthy and developing countries. In line with this, Novavax, Inc. (NASDAQ:NVAX) has reached out to the Serum Institute of India Private Limited (SIIPL) under an exclusive agreement.
The working together of the duo shall accelerate the development of NVX‑CoV2373, Novavax’s COVID‑19 vaccine candidate, and its distribution in several countries. The agreement outlines that the Indian vaccine maker will gain exclusive and non-exclusive rights in all countries apart from the high-income and upper-middle countries.
Ensuring a Global Supply of NVX‑CoV2373 to Regions Significantly Impacted By Coronavirus
As the pandemic continues to rage across the globe, Gavi, the Vaccine Alliance, for the production of two different potential vaccines at SII, explained that the companies want to do thing differently. Both the wealth and the developing countries must be protected equally for international trade, commerce, and society to prosper.
Working with Serum Institute is an advantage for Serum Institute, given that it is the world’s largest vaccine manufacturer by volume. This will only make it easier for the two companies to expand their distribution capacity. The anticipation is to have production of doses as early as the first half of 2021, hoping by then the vaccines will have attained the regulatory approvals.
‘’…Given our experience with Novavax on the development of a malaria vaccine, we know the power of their vaccine technologies…,” Adar Poonawalla, the CEO of SII remarked.
Serum Institute of India Manufactures Life-Saving Immuno-Biologics
No company gets it wrong by partnering with the Indian vaccine maker, founded in 1966. The company produced more than 1.3 billion doses, which have been so successful across the globe. Its founder, Dr. Cyrus Poonawalla, its inception, was guided my one mission, the development of life-saving immuno-biologics.
The company is ranked India’s No. 1 biotechnology company. Besides, statistics indicate that close to 65% of the children across the world have received at least one vaccine manufactured by Serum Institute.